Ibalizumab efficacy and safety through 48 weeks of treatment: Results of an expanded access protocol (TMB-311)

Authors
Category Primary study
JournalOpen Forum Infectious Diseases
Year 2019
This article has no abstract
Epistemonikos ID: b9945d7c5def3f14fd22e2650ccbf8a80f41b9dd
First added on: Feb 11, 2025